PROGNOSTIC FACTOR OF BREAST CANCER AND COVID-19
Abstract
ABSTRACT
Background: Breast cancer is the most commonly diagnosed cancer in the world, and is the leading cause of death from cancer. The prognostic factors of breast cancer are lymph node status, tumor size, estrogen/progesterone receptor (ER/PR) status, histological grade, presence of lympho vascular invasion, Ki-67 proliferation index, age and ethnicity. The COVID-19 pandemic was declared in Bosnia and Herzegovina on March 5, 2020.
The aim of the study was to determine the differences between prognostic factors of breast cancer before and during COVID-19 pandemic.
Patients and methods: This retrospective study covered the period March 2018-March 2022 and included 113 breast cancer patients from Brcko District. The patients were divided into two groups: before (n=66) and during the COVID-19 pandemic (n=47). The average age all patients was 61.99±12.15 years. The prognostic parameters of breast cancer (stage of the disease, menopausal status, histological type, histological grade, expression of Ki-67, tumor size, type of surgery, and axillary lymph node involvement) were analyzed and compared between two groups.
Results: Higher histological grade of breast cancer and more frequent axillary lymph node involvement were observed during the pandemic.
Conclusion: COVID-19 pandemic resulted in more aggressive breast cancer.
Keywords: breast cancer, prognostic factors, COVID-19 pandemic.
References
Ferlay J.; Ervi M.; Lam, F.; Colombet M.; Mery L.; Piñeros M.; Znaor A.; Soerjomataram I.; Bray F. Global Cancer Obser-Vatory: Cancer Today; International Agency for Research on Cancer: Lyon, France, 2020.
Mušanovi?. M.:Rak dojke. U: Mušanovi? M., Obrali? N.,:Onkologija. Bošnja?ki institute Udruženje onkologa BiH, Sarajevo, 249- 262, 2001.
Soerjomataram I, Louwman MW, Ribot JG, Roukema JA, Coebergh JW. An overview of prognostic factors for long-term survivors of breast cancer. Breast Cancer Res. Treat. 2008;107:309–330.
Carter C.L. Allen C. Henson D.E. Relation of tumor size, lymph node status, and survival in 24,740 breast cancer cases. Cancer. 1989; 63: 181-187.
Gerdes J, Lemke H, Baisch H, Wacker HH, Schwab U, Stein H. Cell cycle analysis of a cell proliferation-associated human nuclear antigen defined by the monoclonal antibody Ki-67. J Immunol. 1984;133(4):1710–1715.
N. Zhu, D. Zhang, W. Wang, et al. China Novel Coronavirus Investigating and Research Team. A novel coronavirus from patients with pneumonia in China, 2019 N Engl J Med, 382 (2020), pp. 727-733.
Puca E, ?ivljak R, Arapovi? J, Popescu C, Christova I, Raka L, Cana F, Miranovi? V, Karageorgopoulos D, Baš D, Paglietti B, Bara? A. Short epidemiological overview of the current situation on COVID-19 pandemic in Southeast European (SEE) countries. J Infect Dev Ctries.
Guével E, Priou S, Lamé G, Wassermann J, Bey R, Uzan C, Chatellier G, Belkacemi Y, Tannier X, Guillerm S, Flicoteaux R, Gligorov J, Cohen A, Benderra MA, Teixeira L, Daniel C, Hersant B, Tournigand C, Kempf E; Assistance Publique-Hôpitaux de Paris (AP-HP) Cancer Group, a Cancer Research Application on Big Data (CRAB) initiative. Impact of the COVID-19 pandemic on clinical presentation, treatments, and outcomes of new breast cancer patients: A retrospective multicenter cohort study. Cancer Med. 2023 Nov;12(22):20918-20929.
Antonini M, Pinheiro DJPDC, Matos ABTMB, Ferraro O, Mattar A, Okumura LM, Lopes RGC, Real JM. Impact of the COVID-19 pandemic on the breast cancer early diagnosis program in Brazil. Prev Med Rep. 2023 Apr;32:102157.
Hammond ME, Hayes DF, Dowsett M, et al. American Society of Clinical Oncology/College of American pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer. Arch Pathol Lab Med. 2010;134(6):907–922.11
?lgün AS, Özmen V. The Impact of the COVID-19 Pandemic on Breast Cancer Patients. Eur J Breast Health. 2021 Dec 30;18(1):85-90.
Czajka ML, Pfeifer C. Breast Cancer Surgery. 2023 Feb 8. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2024 Jan–.
Henson DE, Ries L, Freedman LS, Carriaga M: Relationship among outcome, stage of disease, and histologic grade for 22,616 cases of breast cancer. The basis for a prognostic index. Cancer. 1991, 68: 2142-2149.
Rakha EA, El-Sayed ME, Lee AH, Elston CW, Grainge MJ, Hodi Z, Blamey RW, Ellis IO: Prognostic significance of nottingham histologic grade in invasive breast carcinoma. J Clin Oncol. 2008, 26: 3153-3158.
Higgins, Á., O’Reilly, S. & O’Sullivan, M.J. The impact of the COVID-19 pandemic on symptomatic breast cancer presentations in an Irish breast cancer unit: a retrospective cohort study. Ir J Med Sci (2024).16
Higgins, Á., O’Reilly, S. & O’Sullivan, M.J. The impact of the COVID-19 pandemic on symptomatic breast cancer presentations in an Irish breast cancer unit: a retrospective cohort study. Ir J Med Sci (2024).
Borella F, Bertero L, Di Giovanni F et al (2003) COVID-19 and breast cancer: analysis of surgical management of a large referral center during the 2020–2021 pandemic period. Curr Oncol 30(5):4767–4778.
Neri A, Marrelli D, Roviello F, De Stefano A, Guarnieri A, Pallucca E, Pinto E. Prognostic value of extracapsular extension of axillary lymph node metastases in T1 to T3 breast cancer. Ann Surg Oncol. 2005;12:246–253.
Hong R, Dai Z, Zhu W, Xu B. Association between lymph node ratio and disease specific survival in breast cancer patients with one or two positive lymph nodes stratified by different local treatment modalities. PLoS One. 2015;29:e0138908.
Vanni G, Materazzo M, Pellicciaro M, Ingallinella S, Rho M, Santori F, et al. Breast cancer and COVID-19: the effect of fear on patients' decision-making process. In Vivo. 2020;34(3 Suppl):1651–1659.
De Azambuja E, Cardoso F, de Castro G, Colozza M, Jr, Mano MS, Durbecq V, Sotiriou C, Larsimont D, Piccart-Gebhart MJ, Paesmans M. Ki-67 as prognostic marker in early breast cancer: a meta-analysis of published studies involving 12,155 patients. Br J Cancer. 2007;96(10):1504–1513.
Stuart-Harris R, Caldas C, Pinder SE, Pharoah P. Proliferation markers and survival in early breast cancer: a systematic review and meta-analysis of 85 studies in 32,825 patients. Breast. 2008;17:323–334.
Harbeck N, Johnston S, Fasching P, et al. High Ki-67 as a biomarker for identifying patients with high risk early breast cancer treated in monarchE. Cancer Res. 2021;81(suppl 4):PD2-01.
Adachi K, Kimura F, Takahashi H, Kaise H, Yamada K, Ueno E, Kawate T, Miyahara K, Ueda A, Sato S, Asaoka M, Okazaki M, Uenaka N, Orimoto K, Wu R, Koyama Y, Ishikawa T. Delayed Diagnosis and Prognostic Impact of Breast Cancer During the COVID-19 Pandemic. Clin Breast Cancer. 2023 Apr;23(3):265-271.
DOI: 10.5457/ams.v54i2.801
